Display options
Cite
Hays P. Clinical sequelae of the novel coronavirus: does COVID-19 infection predispose patients to cancer?. Future Oncol. 2020;16(20):1463-1474doi: 10.2217/fon-2020-0300.
Hays, P. (2020). Clinical sequelae of the novel coronavirus: does COVID-19 infection predispose patients to cancer?. Future oncology (London, England), 16(20), 1463-1474. https://doi.org/10.2217/fon-2020-0300
Hays, Priya. "Clinical sequelae of the novel coronavirus: does COVID-19 infection predispose patients to cancer?." Future oncology (London, England) vol. 16,20 (2020): 1463-1474. doi: https://doi.org/10.2217/fon-2020-0300
Hays P. Clinical sequelae of the novel coronavirus: does COVID-19 infection predispose patients to cancer?. Future Oncol. 2020 Jul;16(20):1463-1474. doi: 10.2217/fon-2020-0300. Epub 2020 May 27. PMID: 32456461; PMCID: PMC7255429.
Copy Download .nbib Format: NLM
Share it on

Future Oncol. 2020 Jul;16(20):1463-1474. doi: 10.2217/fon-2020-0300. Epub 2020 May 27.

Clinical sequelae of the novel coronavirus: does COVID-19 infection predispose patients to cancer?.

Future oncology (London, England)

Priya Hays

Affiliations

  1. Principal, San Mateo, CA94402, USA.

PMID: 32456461 PMCID: PMC7255429 DOI: 10.2217/fon-2020-0300

Abstract

As cancer patients are clinically known to be predisposed to COVID-19 infection, a corollary question of whether COVID-19 infection predisposes to cancer is explored. This article seeks to establish an association between novel coronavirus sequelae and cancer. A literature review on COVID-19 mechanisms of action, molecular responses it elicits upon infection and tumorigenesis pathways is conducted to establish this association. Major signaling pathways implicated in aberrant cellular growth are activated, the ensuing cytokine storm weakens the immune system response to tumors, and patients may develop cancer as a result of superimposed mutagenic and/or carcinogenic events. Future work needs to be performed to support this hypothesis, both in

Keywords: COVID-19; SARS-CoV-2 ; clinical sequelae; consequences of infection; global pandemic; innate and adaptive immune response; novel coronavirus; oncology

References

  1. Toxins (Basel). 2017 Mar 28;9(4): - PubMed
  2. Front Endocrinol (Lausanne). 2019 May 22;10:330 - PubMed
  3. Cell Physiol Biochem. 2017;42(2):729-742 - PubMed
  4. Eur J Clin Invest. 2015 Jun;45(6):609-23 - PubMed
  5. EBioMedicine. 2018 Nov;37:78-90 - PubMed
  6. J Med Virol. 2020 Apr;92(4):418-423 - PubMed
  7. Cancers (Basel). 2019 Aug 19;11(8): - PubMed
  8. Infect Dis Poverty. 2020 Mar 17;9(1):29 - PubMed
  9. J Gen Virol. 2018 Oct;99(10):1345-1356 - PubMed
  10. J Cell Biochem. 2019 Oct;120(10):17593-17601 - PubMed
  11. Blood. 2018 May 24;131(21):2320-2330 - PubMed
  12. JAMA Neurol. 2020 Jun 1;77(6):683-690 - PubMed
  13. JAMA. 2020 May 26;323(20):2052-2059 - PubMed
  14. J Thromb Haemost. 2020 Jun;18(6):1421-1424 - PubMed
  15. Semin Immunopathol. 2017 Jul;39(5):529-539 - PubMed
  16. JAMA Cardiol. 2020 Jul 1;5(7):802-810 - PubMed
  17. Kidney Int. 2020 Jul;98(1):219-227 - PubMed
  18. Sci Rep. 2018 Jun 22;8(1):9511 - PubMed
  19. J Cell Biochem. 2019 Jan;120(1):894-906 - PubMed
  20. Blood Rev. 2015 Nov;29(6):405-15 - PubMed
  21. Immunity. 2013 Jul 25;39(1):1-10 - PubMed
  22. Zhongguo Fei Ai Za Zhi. 2020 Feb 20;23(3):136-141 - PubMed
  23. J Med Virol. 2020 Apr;92(4):424-432 - PubMed
  24. Int J Cancer. 2019 Dec 15;145(12):3376-3388 - PubMed

MeSH terms

Publication Types